Number of shares and voting rights of Innate Pharma as of January 1, 2024
Innate Pharma strengthens leadership and appoints two new members to its Executive Board
Innate Pharma announces U.S. FDA lifts partial clinical hold on lacutamab clinical program
Innate Pharma Announces Licensing Of A Fourth Natural Killer Cell Engager In Oncology To Sanofi
Innate Pharma Announces Leadership Change
Innate Pharma shares efficacy and safety Phase 1 /2 results of NK Cell Engager SAR443579 / IPH6101 developed by Sanofi at ASH 2023
Innate Pharma presents positive results from TELLOMAK Phase 2 study with lacutamab in patients with Sézary syndrome at ASH 2023
Innate Pharma To Host Virtual Kol Event On Lacutamab
Innate Pharma reports third quarter 2023 financial results and business update
Innate Pharma announces conference call for Third Quarter 2023 Business Update
